CD14 and inflammatory bowel disease: As shown in Fig. 5, mediation effect calculation suggested that Chiro-inositol metabolites reduced the risk of IBD development posed by HLA-DR-expressing CD14 + monocytes, accounting for 4.97% of the effect (level mediated: 4.97%; 95%CI= -3.2–13.2%).